Introduction -- Section 1. Patient/provider checklist -- Section 2. Patient information sheet—PrEP -- Section 3. Patient information sheet—Truvada -- Section 4. Patient information sheet—acute HIV infection and PrEP -- Section 5. Provider Information Sheet—PrEP during conception, pregnancy, and breastfeeding -- Section 6. HIV incidence risk index for men who have sex with men -- Section 7. Supplemental counseling information—medication adherence -- Section 8. Supplemental counseling information—HIV risk reduction -- Section 9. PrEP-related ICD, CPT and LOINC codes -- Section 10. Potential PrEP practice quality measures -- Section 11. Methods for developing the PrEP clinical practice guideline –- References.

This publication provides a comprehensive clinical practice guideline for the use of PrEP for the prevention of HIV infection in the United States. It incorporates and extends information provided in interim guidance for PrEP use with MSM, with heterosexually active adults, and with IDU (also called persons who injection drugs [PWID]). Currently, prescribing daily oral PrEP with TDF/FTC is recommended as one prevention option for MSM, heterosexual men, heterosexual women, and IDU at substantial risk of HIV acquisition. As the results of additional PrEP clinical trials and studies in these and other populations at risk of HIV acquisition become known, this guideline will be updated.

Guidelines and Recommendations

United States